查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088478

流感疫苗市場：2026-2032年全球市場預測（依疫苗類型、年齡層、劑量、配方、通路和最終用戶分類）

Influenza Vaccine Market by Vaccine Type, Age Group, Dosage, Presentation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，流感疫苗市場規模將成長至 179.4 億美元，複合年成長率為 9.65%。

主要市場統計數據
基準年 2025 94.1億美元
預計年份：2026年 102.8億美元
預測年份 2032 179.4億美元
複合年成長率 (%) 9.65%

流感疫苗市場概覽

流感疫苗接種仍然是目前應用最廣泛的公共衛生措施之一，旨在減輕季節性呼吸道疾病帶來的負擔、減少住院人數和可預防的死亡。根據世界衛生組織（世衛組織）估計，季節性流感每年在全球造成約10億人感染，300萬至500萬人重症，29萬至65萬人死於呼吸道疾病。因此，年度免疫接種是醫療衛生系統、雇主、保險公司和疫苗生產商的首要任務。

流感疫苗產業的變革性變化

流感疫苗產業正經歷從季節性供應計畫轉向更具適應性、技術驅動型免疫策略的結構性轉變。雖然雞蛋來源的疫苗仍然是全球供應的主要基礎，但細胞培養疫苗和重組疫苗的重要性日益凸顯，因為它們可以緩解人們對雞蛋適應性的擔憂，並加快生產流程。高劑量疫苗和佐劑合併疫苗對於老年人這個重症高風險族群也變得越來越重要。

人工智慧（AI）的累積影響

人工智慧（AI）正日益成為流感疫苗研發、監測、生產計畫和商業化等各領域的重要驅動力。利用人工智慧分析基因組監測數據，研究人員可以識別新出現的變異株、監測抗原漂移，並確定需要進一步實驗室評估的株優先順序。雖然疫苗病毒株的選擇仍然是一個由全球流感監測網路和專家委員會主導的科學和監管流程，但利用人工智慧可以加速並擴大證據的整合。

關鍵區域洞察

亞太地區是全球最具活力的流感疫苗市場之一，這主要得益於其大規模的人口基數、不斷成長的醫療保健投資以及政府主導的免疫接種計劃的擴大。中國、印度、日本、韓國和澳洲各自發揮獨特的作用，從大規模的國內生產和對兒童免疫接種的需求，到成熟的季節性疫苗接種計劃和先進的疾病監測，都對該地區的發展起到了至關重要的作用。此外，該地區的熱帶和亞熱帶氣候也使流感季節性更加複雜，因此需要靈活的監測措施、根據當地情況調整免疫宣傳活動的時間安排，以及持續進行公共衛生宣傳活動。

對關鍵群體的洞察

隨著東協成員國加強疾病監測、擴大基層醫療範圍並改善都市區居民季節性疫苗接種的可及性，東南亞國協擁有巨大的成長潛力。由於都市區各地流感季節性差異顯著，因此，進行本地化的流行病學分析、靈活的採購方式以及精心設計的疫苗宣傳活動對於提高疫苗接種率和保護高危險群至關重要。

主要國家的概況

美國是流感疫苗的主要市場，這得益於其每年建議全民接種流感疫苗、藥局疫苗供應充足、雇主贊助的疫苗接種計劃以及老年人較高的接種率。在加拿大，各省和地區透過相關項目獲得廣泛的公共資金支持。同時，墨西哥進行全國性宣傳活動，優先考慮兒童、老年人、孕婦、醫護人員和慢性病患者。巴西擁有拉丁美洲規模最大的公共免疫基礎設施之一，並利用其在疫苗供應方面成熟的公共部門經驗，透過季節性宣傳活動大規模覆蓋重點人口。

為行業領導者提供的實用建議

產業領導者應優先考慮生產平台的多元化，以平衡成本、規模和性能。雖然以雞蛋為基礎的生產方式仍然重要，但投資於基於細胞培養、重組、佐劑、高劑量以及最終基於mRNA的流感疫苗，將有助於增強應對病毒株不匹配和供應中斷的能力。

調查方法

本執行摘要採用系統性的二手調查方法編寫，依據公共衛生、監管和科學領域的權威資訊來源。主要資訊來源包括世界衛生組織流感疾病負擔估計和毒株選擇過程、美國疾病控制與預防中心疫苗接種建議、歐洲公共衛生指南、國家免疫政策、美國食品藥品監督管理局（FDA）和歐洲藥品管理局（EMA）等監管機構的信息，以及關於疫苗效力、生產平台和流感流行病學的同行評審證據。

結論

流感疫苗市場的特點是全球需求持續旺盛、病毒流行病學不斷演變，以及人們對更快、更有效、更便利的免疫接種的期望日益成長。由於流感持續在全球造成嚴重的疾病和死亡，尤其是在老年人、嬰幼兒、孕婦、醫護人員和患有基礎疾病的人群中，因此年度疫苗接種仍將是公共衛生政策的核心。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 流感疫苗市場：依疫苗類型分類

  • 失活
  • 減毒活病毒疫苗
  • 重組

第8章：流感疫苗市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第9章：流感疫苗市場：依劑量分類

  • 多劑量
  • 單一劑量

第10章：流感疫苗市場：以劑型分類

  • 預填充式注射器
    • 玻璃預充式預填充式注射器
    • 塑膠預填充式注射器
  • 管瓶
    • 多管瓶小瓶
    • 單劑量管瓶

第11章：流感疫苗市場：依分銷管道分類

  • 直銷
  • 醫院藥房

第12章：流感疫苗市場：依最終用戶分類

  • 診所
    • 門診部
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院

第13章：流感疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：流感疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 流感疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Adimmune Corporation
  • Altimmune, Inc.
  • AstraZeneca plc
  • Bharat Biotech International Limited
  • BIKEN Co., Ltd.
  • BioDiem Ltd.
  • Changchun BCHT Biotechnology Co.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • FluGen, Inc.
  • GlaxoSmithKline plc
  • Hualan Biological Engineering Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi
  • Seqirus Pty Ltd
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • SK bioscience Co., Ltd.
  • Valneva SE
  • Viatris Inc.
Product Code: MRR-032A67D913E1

The Influenza Vaccine Market is projected to grow by USD 17.94 billion at a CAGR of 9.65% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.41 billion
Estimated Year [2026] USD 10.28 billion
Forecast Year [2032] USD 17.94 billion
CAGR (%) 9.65%

Influenza Vaccine Market Overview

Influenza vaccination remains one of the most widely used public health interventions for reducing seasonal respiratory disease burden, hospitalizations, and preventable deaths. The World Health Organization (WHO) estimates that seasonal influenza causes approximately 1 billion infections, 3 million to 5 million severe cases, and 290,000 to 650,000 respiratory deaths globally each year, making annual immunization a persistent priority for health systems, employers, payers, and vaccine manufacturers.

The influenza vaccine landscape is shaped by recurring demand, evolving viral strains, government procurement, and the need for timely production ahead of each flu season. Because influenza viruses undergo frequent antigenic drift, WHO convenes twice yearly to recommend vaccine composition for the Northern and Southern Hemisphere influenza seasons. This creates a uniquely cyclical market in which strain surveillance, manufacturing speed, cold-chain readiness, and public confidence directly influence vaccine availability and uptake.

Growth opportunities are strongest where influenza immunization programs are expanding beyond high-risk groups to broader adult, pediatric, workplace, pharmacy-based, and community access models. At the same time, the industry is moving from traditional egg-based manufacturing toward cell-based influenza vaccines, recombinant influenza vaccines, adjuvanted vaccines, high-dose flu vaccines, and next-generation platforms designed to improve effectiveness, scalability, and resilience against strain mismatch.

Transformative Shifts in the Influenza Vaccine Landscape

The influenza vaccine industry is undergoing a structural shift from seasonal supply planning to more adaptive, technology-enabled immunization strategies. Egg-based vaccines continue to serve as a major global supply backbone, but cell-based and recombinant vaccines are gaining relevance because they can reduce egg-adaptation concerns and support faster production workflows. High-dose and adjuvanted formulations are also increasingly important for older adults, who experience higher risks of severe influenza outcomes.

Access channels are changing as well. In the United States and several other mature markets, pharmacies, retail clinics, employer programs, and digital appointment systems have made influenza vaccination more convenient. In Europe, national immunization programs continue to prioritize older adults, pregnant individuals, healthcare workers, and people with chronic conditions, while policy emphasis is growing around improving coverage after pandemic-era disruptions.

The competitive landscape is also being reshaped by lessons from COVID-19 vaccine deployment. Governments and manufacturers are placing greater emphasis on supply security, regional manufacturing capacity, real-world evidence, and public communication. These changes are increasing demand for flexible production platforms, reliable pharmacovigilance, and evidence-based outreach that addresses vaccine hesitancy, misinformation, and uneven access across population groups.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across influenza vaccine research, surveillance, production planning, and commercialization. AI-assisted analysis of genomic surveillance data can help researchers identify emerging variants, monitor antigenic drift, and prioritize strains for further laboratory assessment. While vaccine strain selection remains a scientific and regulatory process led by global influenza surveillance networks and expert committees, AI can improve the speed and scale of evidence synthesis.

AI is also supporting clinical development and real-world evidence generation. Machine learning can assist in trial site selection, population stratification, safety signal detection, and post-marketing effectiveness analysis using large healthcare datasets. These capabilities are particularly important for influenza vaccines because effectiveness varies by season, age group, circulating strain, and vaccine platform.

Commercially, AI can improve demand forecasting, inventory allocation, and outreach timing. Health systems, pharmacies, and public health agencies can use predictive analytics to identify communities with historically low vaccination rates, optimize appointment capacity, reduce wastage, and refine communication windows before peak influenza activity. The cumulative impact is not the replacement of established scientific oversight, but a more responsive influenza vaccine ecosystem with better surveillance intelligence, more efficient operations, and more targeted public health engagement.

Key Regional Insights

Asia-Pacific is one of the most dynamic influenza vaccine regions due to large population bases, rising healthcare investment, and government-led immunization expansion. China, India, Japan, South Korea, and Australia each play distinct roles, ranging from large-scale domestic production and pediatric immunization demand to mature seasonal vaccination programs and advanced disease surveillance. The region's tropical and subtropical climates also create complex influenza seasonality, requiring flexible surveillance, localized campaign timing, and sustained public health communication.

North America remains highly developed for seasonal flu vaccine access, supported by strong annual recommendations, broad pharmacy delivery, employer-sponsored vaccination, and established reimbursement systems. The U.S. Centers for Disease Control and Prevention recommends annual influenza vaccination for everyone aged 6 months and older, creating a stable policy foundation for recurring immunization. Canada similarly supports seasonal influenza vaccination through provincial and territorial programs that prioritize risk groups while enabling broader community access.

Latin America is advancing through public-sector procurement, national immunization campaigns, and increasing attention to adult, pediatric, and maternal vaccination. Brazil and Mexico are central demand anchors because of their large public health systems and recurring seasonal campaigns, while other countries continue strengthening coverage among older adults, children, healthcare workers, pregnant individuals, and people with chronic disease.

Europe benefits from mature regulatory oversight, national immunization technical advisory groups, and strong public health infrastructure. The European Union emphasizes vaccine safety monitoring, coordinated disease surveillance, and improved coverage among older adults and medical risk groups. The Middle East is supported by GCC healthcare modernization, travel medicine needs, pilgrimage-related preventive health planning, and growing investment in preventive care. Africa remains a critical access region where influenza vaccination is concentrated in priority groups and constrained by financing, awareness, healthcare workforce capacity, and cold-chain infrastructure, even as surveillance improvements strengthen the evidence base for influenza immunization programs.

Key Group Insights

ASEAN presents meaningful growth potential as member states strengthen disease surveillance, expand primary care, and improve access to seasonal immunization in urban and semi-urban populations. Influenza seasonality across Southeast Asia can vary substantially, making localized epidemiology, flexible procurement, and campaign design essential for improving vaccine uptake and protecting high-risk groups.

The GCC is characterized by relatively advanced healthcare infrastructure, high inbound and outbound travel, and strong government capacity to implement preventive health campaigns. Influenza vaccination is particularly relevant for healthcare workers, people with chronic conditions, older adults, and pilgrims or travelers moving through major regional hubs, where respiratory disease prevention supports both population health and health system readiness.

The European Union provides a coordinated regulatory and surveillance environment while allowing country-level immunization strategies. EU priorities include increasing coverage in older adults and medical risk groups, supporting pharmacovigilance, improving cross-border disease intelligence, and sustaining public trust through transparent vaccine safety communication.

BRICS countries collectively represent a major share of global population and future vaccine demand. Brazil, Russia, India, China, and South Africa combine large public health needs with growing domestic manufacturing capabilities and policy interest in vaccine security. G7 countries remain influential through advanced R&D ecosystems, premium vaccine adoption, funding capacity, and global health partnerships. NATO member countries are also relevant because military readiness, healthcare worker protection, emergency preparedness, and resilient medical supply chains reinforce the strategic value of reliable influenza vaccine supply.

Key Country Insights

The United States is a leading market for influenza vaccines due to universal annual vaccination recommendations, extensive pharmacy delivery, employer programs, and strong uptake among older adults. Canada maintains broad public funding through provincial and territorial programs, while Mexico relies on national campaigns that prioritize children, older adults, pregnant individuals, healthcare workers, and people with chronic conditions. Brazil has one of Latin America's largest public immunization infrastructures and uses seasonal campaigns to reach priority groups at scale, supported by established public-sector vaccine delivery experience.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature influenza vaccination programs supported by national guidance and public reimbursement for eligible groups. The United Kingdom has expanded convenient access through general practice and pharmacy channels, while Germany and France emphasize risk-based recommendations, medical professional engagement, and coverage improvement. Italy and Spain remain important markets due to aging populations and recurring public health campaigns focused on older adults and vulnerable groups. Russia combines domestic vaccine production capacity with national immunization priorities across risk groups and public health institutions.

In Asia-Pacific, China and India represent large long-term opportunities because of population scale, expanding healthcare access, local manufacturing capability, and growing awareness of adult immunization. Japan is a mature market with strong demand among older adults and established seasonal vaccination practices. Australia's Southern Hemisphere influenza season provides important epidemiological intelligence for global strain monitoring and vaccine composition discussions, while South Korea combines advanced healthcare infrastructure with strong domestic biotechnology capability and seasonal immunization programs that support high-risk populations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platform diversification to balance cost, scale, and performance. Egg-based manufacturing will remain important, but investment in cell-based, recombinant, adjuvanted, high-dose, and potentially mRNA-based influenza vaccines can improve resilience against strain mismatch and supply disruption.

Manufacturers and healthcare stakeholders should strengthen real-world evidence capabilities by tracking vaccine effectiveness by age, risk group, strain, and platform. This evidence is essential for payer engagement, public trust, clinical guideline support, and differentiated product positioning in competitive tenders and national immunization programs.

Commercial teams should expand access through pharmacies, workplaces, schools where permitted, digital scheduling, mobile clinics, and targeted reminders. Public health partners should focus messaging on high-risk groups, including older adults, pregnant individuals, young children, healthcare workers, and people with chronic conditions. Across emerging markets, partnerships that improve cold-chain capacity, healthcare worker training, financing pathways, and local surveillance can unlock sustainable demand while strengthening influenza preparedness.

Research Methodology

This executive summary is developed using a structured secondary research methodology grounded in authoritative public health, regulatory, and scientific sources. Core inputs include WHO influenza burden estimates and strain-selection processes, CDC vaccination recommendations, European public health guidance, national immunization policies, regulatory information from agencies such as the FDA and EMA, and peer-reviewed evidence on vaccine effectiveness, manufacturing platforms, and influenza epidemiology.

The analysis triangulates epidemiological burden, immunization policy, access channels, technology trends, and regional healthcare infrastructure. It avoids unsupported market sizing claims and focuses on verifiable drivers such as annual vaccination recommendations, demographic risk, surveillance systems, platform innovation, procurement dynamics, safety monitoring, and government-led prevention priorities.

Insights are organized to support executive decision-making across strategy, market access, product planning, and regional prioritization. All content is written in original language for web publication and optimized around industry-relevant terms including influenza vaccine market, seasonal flu vaccine, recombinant influenza vaccine, cell-based influenza vaccine, high-dose flu vaccine, flu shot, and influenza immunization programs.

Conclusion

The influenza vaccine market is defined by recurring global need, evolving viral epidemiology, and rising expectations for faster, more effective, and more accessible immunization. Annual vaccination will remain central to public health policy because influenza continues to cause substantial severe disease and mortality worldwide, particularly among older adults, young children, pregnant individuals, healthcare workers, and people with underlying medical conditions.

The next phase of industry advancement will be driven by improved vaccine platforms, stronger surveillance, AI-enabled forecasting and operations, broader retail and community access, and targeted communication that addresses hesitancy. Organizations that combine scientific credibility, manufacturing flexibility, regional partnerships, and real-world evidence will be best positioned to compete in this essential segment of preventive healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Influenza Vaccine Market, by Vaccine Type

  • 7.1. Inactivated
  • 7.2. Live Attenuated
  • 7.3. Recombinant

8. Influenza Vaccine Market, by Age Group

  • 8.1. Adult
  • 8.2. Geriatric
  • 8.3. Pediatric

9. Influenza Vaccine Market, by Dosage

  • 9.1. Multi Dose
  • 9.2. Single Dose

10. Influenza Vaccine Market, by Presentation

  • 10.1. Prefilled Syringe
    • 10.1.1. Glass Prefilled Syringe
    • 10.1.2. Plastic Prefilled Syringe
  • 10.2. Vial
    • 10.2.1. Multi Dose Vial
    • 10.2.2. Single Dose Vial

11. Influenza Vaccine Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Hospital Pharmacies

12. Influenza Vaccine Market, by End User

  • 12.1. Clinics
    • 12.1.1. Outpatient Clinics
    • 12.1.2. Specialty Clinics
  • 12.2. Hospitals
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals

13. Influenza Vaccine Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Influenza Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Influenza Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Adimmune Corporation
  • 17.3. Altimmune, Inc.
  • 17.4. AstraZeneca plc
  • 17.5. Bharat Biotech International Limited
  • 17.6. BIKEN Co., Ltd.
  • 17.7. BioDiem Ltd.
  • 17.8. Changchun BCHT Biotechnology Co.
  • 17.9. CSL Limited
  • 17.10. Daiichi Sankyo Company, Limited
  • 17.11. FluGen, Inc.
  • 17.12. GlaxoSmithKline plc
  • 17.13. Hualan Biological Engineering Inc.
  • 17.14. Merck & Co., Inc.
  • 17.15. Mitsubishi Tanabe Pharma Corporation
  • 17.16. Moderna, Inc.
  • 17.17. Novavax, Inc.
  • 17.18. Pfizer Inc.
  • 17.19. Sanofi
  • 17.20. Seqirus Pty Ltd
  • 17.21. Serum Institute of India Pvt. Ltd.
  • 17.22. Sinovac Biotech Ltd.
  • 17.23. SK bioscience Co., Ltd.
  • 17.24. Valneva SE
  • 17.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INFLUENZA VACCINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INFLUENZA VACCINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INFLUENZA VACCINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTI DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTI DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTI DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLASS PREFILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLASS PREFILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLASS PREFILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PLASTIC PREFILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLASTIC PREFILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PLASTIC PREFILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTI DOSE VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTI DOSE VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTI DOSE VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SINGLE DOSE VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SINGLE DOSE VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SINGLE DOSE VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIRECT SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIRECT SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIRECT SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GCC INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 160. GCC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. G7 INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 190. G7 INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 193. G7 INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. NATO INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 204. NATO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. NATO INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NATO INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. FRANCE INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 285. FRANCE INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 302. ITALY INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 303. ITALY INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 304. ITALY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. ITALY INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. ITALY INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 307. ITALY INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 314. SPAIN INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 315. SPAIN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. SPAIN INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. SPAIN INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 318. SPAIN INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 334. INDIA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 335. INDIA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 336. INDIA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 337. INDIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 338. INDIA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. INDIA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 340. INDIA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. JAPAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. JAPAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 344. JAPAN INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 345. JAPAN INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 346. JAPAN INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 347. JAPAN INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 348. JAPAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 349. JAPAN INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 350. JAPAN INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 351. JAPAN INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 352. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 355. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 356. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 357. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 358. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 360. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 361. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 362. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 364. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 365. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 366. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 367. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 368. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 369. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 370. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 371. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 372. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 373. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)